Edinburgh Research Explorer

Prof David Cameron

Chair of Oncology/Head of Cancer Services

Profile photo

Biography

Prof. Cameron received his medical degree in 1986 from St. George’s Hospital Medical School, London. After completing a fellowship and MSc in Clinical Oncology at the University of Edinburgh, he received a M.D. with distinction in 1997. Prof. Cameron is a member of several professional societies including the American Society of Clinical Oncology, the European Society for Medical Oncology and is Secretary of the European Organisation for Research and Treatment of Cancer (EORTC) Breast Cancer Group. He has also been a member of the EORTC task force on the use of growth factors in chemotherapy for solid tumours and lymphoma and Chairman of the EORTC New Agent Committee.

 

He is active in a number of clinical trials in breast cancer.  He is a member of the executive committee of the HERA adjuvant herceptin trial, and is a member of the steering group for several UK adjuvant breast cancer trials (AZURE, OPTION, TACT, TANGO and TEAM). He is chief investigator on the recent UK trial adjuvant breast cancer trial, TACT2, exploring the benefit of accelerated Epirubicin chemotherapy in the treatment of breast cancer, and chief investigator of BEATRICE, a global trial testing the possible benefit of adjuvant bevacizumab in triple negative breast cancer

 

Between November 2006 & June 2010 he was Director of the NIHR-funded National Cancer Research Networks, and continues as an Associate Director. He recently took up a new post as Professor of Oncology at Edinburgh University and Director of Cancer Services in NHS Lothian.  He continues his major clinical interest in breast cancer with an on-going clinical and translational research programme.

Research Interests

The Edinburgh Cancer Research Centre is committed to identifying potential new approaches to treating and preventing cancer.  Being on the same campus as the Edinburgh Cancer Centre, the Edinburgh Breast unit and the regional colorectal, neurological and urological surgical departments, it is in an ideal position to work closely with NHS cancer services.  Many clinicians either run laboratory groups or collaborate with laboratory researchers to enable local patients to contribute to and benefit from new research into cancer.

There is a close-knit team of staff providing support for clinical trials in cancer patients, funded by Cancer Research UK, ECMC, Chief Scientist’s office via NHS R&D, and other local charities and funding sources.  These staff are jointly managed to enable as many patients as possible to be offered the opportunity to enrol in clinical studies, from phase I “first in man” studies right through to late-stage randomised clinical trials.

ID: 6737